What is Palatin?
Founded in 1986 and headquartered in Cranbury, New Jersey, Palatin Technologies specializes in the development of melanocortin receptor agonists. The company's primary asset, Bremelanotide, is currently undergoing Phase III clinical evaluation for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Beyond its flagship program, Palatin maintains a robust R&D portfolio targeting conditions such as erectile dysfunction, obesity, diabetes, and inflammatory dermatologic diseases. By leveraging its proprietary peptide platform, the company occupies a critical niche in the biopharmaceutical sector, focusing on high-unmet-need therapeutic areas that require precise, receptor-specific intervention. Their strategic focus on natriuretic peptide receptor-specific programs, including PL-3994 for heart failure and asthma, further underscores their commitment to diversifying their clinical footprint.
How much funding has Palatin raised?
Palatin has raised a total of $93.8M across 9 funding rounds:
Other Financing Round
$1.8M
Multiple Rounds
$31.9M
Share Placement
$19.8M
Debt
$10M
Share Placement
$9.2M
Share Placement
$16.5M
Other Financing Round
$4.7M
Other Financing Round (2013): $1.8M with participation from Commercialization Center for Innovative Technologies
Other Financing Round (2014): $1.9M led by Commercialization Center for Innovative Technologies
Share Placement (2014): $20M supported by QVT Financial
Debt (2014): $10M featuring Horizon Technology Finance Corporation
Share Placement (2015): $19.8M backed by QVT Financial
Debt (2015): $10M with participation from Horizon Technology Finance Corporation
Share Placement (2016): $9.2M, investors not publicly disclosed
Share Placement (2016): $16.5M, investors not publicly disclosed
Other Financing Round (2023): $4.7M featuring Commercialization Center for Innovative Technologies
Key Investors in Palatin
QVT Financial
QVT Family Office is composed of a diverse group of original thinkers with non-traditional backgrounds, offering unique expertise in smart investment strategies. The firm focuses on various core areas including biotech, technology, energy, financials, and opportunistic investments.
Horizon Technology Finance Corporation
Horizon Technology Finance is a specialty finance company that operates within the broader financial services sector, focusing on providing structured debt financing solutions to development-stage companies.
Commercialization Center for Innovative Technologies
An investment entity focused on supporting the commercialization of innovative technologies and early-stage scientific advancements.
What's next for Palatin?
With the infusion of recent capital, Palatin is well-positioned to accelerate its clinical milestones and transition its preclinical candidates into human trials. The company's strategic roadmap emphasizes the successful commercialization of its lead assets while simultaneously de-risking its broader pipeline through disciplined R&D investment. As the firm moves forward, stakeholders will likely monitor the progression of its Phase III HSDD studies and the potential expansion of its melanocortin receptor-4 (MC4r) programs. By maintaining a lean operational structure and focusing on high-value therapeutic indications, Palatin aims to solidify its market position as a leader in peptide-based medicine, potentially unlocking significant value through future licensing agreements or strategic partnerships in the global healthcare market.
See full Palatin company page
